BRPI0411335A - método para preparar uma formulação de estradiol de liberação lenta, formulação farmacêutica, microesferas de estradiol e colesterol, método para efetuar contracepção e terapia de reposição hormonal simultáneas, e, kit - Google Patents
método para preparar uma formulação de estradiol de liberação lenta, formulação farmacêutica, microesferas de estradiol e colesterol, método para efetuar contracepção e terapia de reposição hormonal simultáneas, e, kitInfo
- Publication number
- BRPI0411335A BRPI0411335A BRPI0411335A BRPI0411335A BR PI0411335 A BRPI0411335 A BR PI0411335A BR PI0411335 A BRPI0411335 A BR PI0411335A BR PI0411335 A BRPI0411335 A BR PI0411335A
- Authority
- BR
- Brazil
- Prior art keywords
- estradiol
- formulation
- replacement therapy
- kit
- preparing
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 229960005309 estradiol Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 238000002657 hormone replacement therapy Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title 2
- 229930182833 estradiol Natural products 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 239000004005 microsphere Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000000186 progesterone Substances 0.000 abstract 2
- 229960003387 progesterone Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODO PARA PREPARAR UMA FORMULAçãO DE ESTRADIOL DE LIBERAçãO LENTA, FORMULAçãO FARMACêUTICA, MICROESFERAS DE ESTRADIOL E COLESTEROL, MéTODO PARA EFETUAR CONTRACEPçãO E TERAPIA DE REPOSIçãO HORMONAL SIMULTáNEAS, E, KIT". A presente invenção proporciona formulações de estradiol-progesterona de liberação lenta que podem ser usadas quer em contracepção quer em terapias de reposição hormonal. As formulações compreendem partículas moldadas de estradiol que estão em uma forma semicristalina que exibem velocidades de dissolução especialmente lentas. As partículas moldadas compreendem estradiol composto em uma razão molar 1:1 com colesterol, e são administradas em combinação com progesterona. As formulações de liberação lenta da presente invenção conferem as vantagens duplas de uma formulação de estradiol de dose lenta com um regime de administração de freqüência baixa. As formulações podem ser parenteralmente administradas uma vez ao mês ou menos freqüentemente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47793903P | 2003-06-13 | 2003-06-13 | |
| PCT/IB2004/001930 WO2004110408A2 (en) | 2003-06-13 | 2004-06-10 | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0411335A true BRPI0411335A (pt) | 2006-07-25 |
Family
ID=33551788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411335 BRPI0411335A (pt) | 2003-06-13 | 2004-06-10 | método para preparar uma formulação de estradiol de liberação lenta, formulação farmacêutica, microesferas de estradiol e colesterol, método para efetuar contracepção e terapia de reposição hormonal simultáneas, e, kit |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7589082B2 (pt) |
| EP (3) | EP1820494B1 (pt) |
| JP (2) | JP4956185B2 (pt) |
| CN (2) | CN100594907C (pt) |
| AT (1) | ATE454885T1 (pt) |
| AU (1) | AU2004246870B2 (pt) |
| BR (1) | BRPI0411335A (pt) |
| CA (2) | CA2528545C (pt) |
| CY (1) | CY1109967T1 (pt) |
| DE (1) | DE602004025156D1 (pt) |
| DK (3) | DK1820494T3 (pt) |
| EA (3) | EA026709B1 (pt) |
| ES (3) | ES2340422T3 (pt) |
| HU (1) | HUE025147T2 (pt) |
| IL (2) | IL172466A (pt) |
| MX (1) | MX2008014654A (pt) |
| NO (1) | NO341540B1 (pt) |
| OA (1) | OA13307A (pt) |
| PL (3) | PL1663161T3 (pt) |
| PT (3) | PT1820494E (pt) |
| SI (3) | SI1820494T1 (pt) |
| TW (1) | TWI336623B (pt) |
| WO (1) | WO2004110408A2 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340422T3 (es) | 2003-06-13 | 2010-06-02 | Skendi Finance, Ltd. | Microparticulas constituidas por estradiol y colesterol. |
| JP2011516606A (ja) * | 2008-04-14 | 2011-05-26 | ポジ ビジョナリー ソリューションズ エルエルピー | 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物 |
| UY33103A (es) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico |
| WO2012129305A1 (en) * | 2011-03-23 | 2012-09-27 | Pop Test Cortisol Llc | Combination therapy |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3174542A4 (en) | 2014-07-29 | 2018-01-03 | TherapeuticsMD, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| ITUB20153652A1 (it) * | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| BR112018069877A2 (pt) * | 2016-04-01 | 2019-02-05 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteróide |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| EP3272732B1 (de) | 2016-07-19 | 2019-09-18 | Evonik Degussa GmbH | Verfahren zur alkoxycarbonylierung ethylenisch ungesättigter verbindungen mit monophosphinliganden |
| KR102954589B1 (ko) * | 2018-11-29 | 2026-04-20 | 인시그나 인크. | 불임제로서의 에스트라디올 벤조에이트 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| EP3954364A1 (en) * | 2020-08-14 | 2022-02-16 | Chemo Research, S.L. | New modified release oral contraceptive composition |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| GB1367608A (en) * | 1973-03-09 | 1974-09-18 | Biolog Concepts Inc | Oral pharmaceutical dosage form |
| US4218255A (en) * | 1976-08-30 | 1980-08-19 | University Of Dayton | Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method |
| US4180560A (en) * | 1976-10-26 | 1979-12-25 | Syntex Corporation | Inert core implant pellet |
| JPS5799562A (en) | 1980-12-12 | 1982-06-21 | Nippon Shinyaku Co Ltd | Preparation of microcrystal |
| US5023092A (en) | 1988-06-16 | 1991-06-11 | Ici Americas Inc. | Mannitol having gamma sorbitol polymorph |
| IT1230566B (it) | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| FR2663223B1 (fr) | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
| FR2663224B1 (fr) * | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| IE71203B1 (en) * | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
| IE62665B1 (en) * | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
| SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| DE4130173A1 (de) | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
| SE9301171D0 (sv) * | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
| TW360548B (en) | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
| FR2747042B1 (fr) * | 1996-04-05 | 1998-06-05 | Besins Iscovesco Lab | Medicament a base de progesterone et d'oestradiol |
| US5762956A (en) * | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| EP0888790A1 (en) | 1997-07-04 | 1999-01-07 | PowderJect Research Limited | Drug particle delivery device |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| DK1361881T3 (da) * | 2000-12-14 | 2006-02-20 | Ortho Mcneil Pharm Inc | Steroide hormonprodukter og fremgangsmåder til fremstilling heraf |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| ES2340422T3 (es) | 2003-06-13 | 2010-06-02 | Skendi Finance, Ltd. | Microparticulas constituidas por estradiol y colesterol. |
-
2004
- 2004-06-10 ES ES07008942T patent/ES2340422T3/es not_active Expired - Lifetime
- 2004-06-10 ES ES04736545.7T patent/ES2537551T3/es not_active Expired - Lifetime
- 2004-06-10 DK DK07008942T patent/DK1820494T3/da active
- 2004-06-10 WO PCT/IB2004/001930 patent/WO2004110408A2/en not_active Ceased
- 2004-06-10 CN CN200480023175A patent/CN100594907C/zh not_active Expired - Fee Related
- 2004-06-10 OA OA1200500357A patent/OA13307A/en unknown
- 2004-06-10 CA CA2528545A patent/CA2528545C/en not_active Expired - Fee Related
- 2004-06-10 AT AT07008942T patent/ATE454885T1/de active
- 2004-06-10 CA CA2849228A patent/CA2849228C/en not_active Expired - Fee Related
- 2004-06-10 EP EP20070008942 patent/EP1820494B1/en not_active Expired - Lifetime
- 2004-06-10 CN CN200910258692.9A patent/CN101816662B/zh not_active Expired - Fee Related
- 2004-06-10 DK DK04736545.7T patent/DK1663161T3/en active
- 2004-06-10 DK DK07008938.8T patent/DK1844765T3/en active
- 2004-06-10 HU HUE04736545A patent/HUE025147T2/hu unknown
- 2004-06-10 SI SI200431384T patent/SI1820494T1/sl unknown
- 2004-06-10 PT PT07008942T patent/PT1820494E/pt unknown
- 2004-06-10 MX MX2008014654A patent/MX2008014654A/es active IP Right Grant
- 2004-06-10 BR BRPI0411335 patent/BRPI0411335A/pt not_active Application Discontinuation
- 2004-06-10 EA EA201201221A patent/EA026709B1/ru not_active IP Right Cessation
- 2004-06-10 AU AU2004246870A patent/AU2004246870B2/en not_active Ceased
- 2004-06-10 PL PL04736545T patent/PL1663161T3/pl unknown
- 2004-06-10 SI SI200432235T patent/SI1663161T1/sl unknown
- 2004-06-10 EA EA200600029A patent/EA012783B1/ru not_active IP Right Cessation
- 2004-06-10 DE DE200460025156 patent/DE602004025156D1/de not_active Expired - Lifetime
- 2004-06-10 PL PL07008942T patent/PL1820494T3/pl unknown
- 2004-06-10 EP EP20040736545 patent/EP1663161B1/en not_active Expired - Lifetime
- 2004-06-10 PT PT70089388T patent/PT1844765E/pt unknown
- 2004-06-10 ES ES07008938.8T patent/ES2537563T3/es not_active Expired - Lifetime
- 2004-06-10 US US10/864,470 patent/US7589082B2/en not_active Expired - Fee Related
- 2004-06-10 PT PT47365457T patent/PT1663161E/pt unknown
- 2004-06-10 SI SI200432238T patent/SI1844765T1/sl unknown
- 2004-06-10 PL PL07008938T patent/PL1844765T3/pl unknown
- 2004-06-10 EA EA200900451A patent/EA018356B1/ru not_active IP Right Cessation
- 2004-06-10 JP JP2006516535A patent/JP4956185B2/ja not_active Expired - Fee Related
- 2004-06-10 EP EP20070008938 patent/EP1844765B1/en not_active Expired - Lifetime
- 2004-06-14 TW TW93117058A patent/TWI336623B/zh not_active IP Right Cessation
-
2005
- 2005-12-08 IL IL172466A patent/IL172466A/en active IP Right Grant
-
2006
- 2006-01-13 NO NO20060200A patent/NO341540B1/no not_active IP Right Cessation
-
2008
- 2008-12-02 US US12/326,316 patent/US8163722B2/en not_active Expired - Fee Related
-
2010
- 2010-04-12 CY CY101100328T patent/CY1109967T1/el unknown
-
2011
- 2011-01-25 IL IL210851A patent/IL210851A/en active IP Right Grant
- 2011-04-06 JP JP2011084716A patent/JP2011157386A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE454885T1 (de) | Mikrosphären von estradiol und cholesterol | |
| DK1272504T3 (da) | 8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener | |
| BR0312054A (pt) | Uso de derivados de tio-oxindol na preparação de medicamentos úteis no tratamento de condições relacionadas com hormÈnio, e kit farmacêutico | |
| KR20010052763A (ko) | 디하이드로에피안드로스테론(ｄｈｅａ) 또는 그 동족체와복합한 선택적인 에스트로겐 수용체 조절자 | |
| BR0114665A (pt) | Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio | |
| PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
| EA200301022A1 (ru) | Гормональная заместительная терапия | |
| BR0312140A (pt) | Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazes | |
| BRPI0509209A (pt) | composto, métodos para contracepção, terapia de reposição hormonal, tratamento ou prevenção de doença neoplásica dependente de hormÈnios; tratamento de sangramento disfuncional ou da sìndrome de ovários policìsticos; sincronização do estro; tratamento da acne ou tratamento do hirsutismo, e para preparação do composto, composição farmacêutica, kit farmacêutico, e, uso de um composto | |
| YU77302A (sh) | 8beta-hidrokarbil-supstituisani estratrieni kao selektivno delotvorni estrogeni | |
| AR033260A1 (es) | Nueva composicion hormonal y su utilizacion | |
| BRPI0511864A (pt) | uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento | |
| BR0314959A (pt) | Emplastro transdérmico de 17beta-estradiol/levonorgestrel para terapia de reposição hormonal | |
| CY1116203T1 (el) | Σκευασμα οιστραδιολης-προγεστερονης βραδειας αποδεσμευσης | |
| BR0309621A (pt) | Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios | |
| AR032371A1 (es) | Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| BRPI0514119A (pt) | polimorfo cristalino de monoidrato de hidrocloreto de pipindoxifeno, composição, método de preparação da forma i polimórfica de hidrocloreto de pipindoxifeno, forma i polimórfica de hidrocloreto de pinpidoxifeno, método de conversão da forma i de monoidrato de hidrocloreto de pipindoxifeno na forma ii, métodos de tratamento de um mamìfero tendo uma doença ou sìndrome ou um distúrbio, métodos para reduzir colesterol, para inibir a perda óssea e para tratar cáncer de mama em um mamìfero,método de tratamento de uma mulher na pós-menopausa quanto a um ou mais distúrbios vasomotores,e , uso de um polimorfo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |